NASDAQ:QTNT - Quotient Stock Price, Price Target & More

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient (NASDAQ:QTNT) announced its earnings results on Monday, May, 22nd. The company reported ($0.69) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.07. The business had revenue of $5.53 million for the quarter, compared to the consensus estimate of $4.30 million. View Quotient's Earnings History.

Quotient is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for Quotient.

2 brokers have issued 1 year price targets for Quotient's stock. Their predictions range from $10.00 to $13.00. On average, they expect Quotient's share price to reach $11.50 in the next year. View Analyst Ratings for Quotient.

Some companies that are related to Quotient include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO), GeneNews (GNWSF) and FluoroPharma Medical (FPMI).

Press coverage about QTNT stock has trended somewhat positive on Saturday, according to Accern. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quotient earned a daily sentiment score of 0.16 on Accern's scale. They also assigned press coverage about the company an impact score of 46.82 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Quotient's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Highbridge Capital Management LLC (4.40%), BlackRock Inc. (2.62%), Prosight Management LP (1.50%), Knott David M (0.35%), Opaleye Management Inc. (0.13%) and Birchview Capital LP (0.09%). Company insiders that own Quotient stock include Brian Mcdonough, D J Paul E Cowan, Jeremy Stackawitz, L John Wilkerson, Life Sciences Maste Perceptive, Prondzynski Heino Von and Stephen Unger. View Institutional Ownership Trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Prosight Management LP, Birchview Capital LP and BlackRock Inc.. View Insider Buying and Selling for Quotient.

QTNT stock was purchased by a variety of institutional investors in the last quarter, including Knott David M, Opaleye Management Inc. and The Manufacturers Life Insurance Company . Company insiders that have bought Quotient stock in the last two years include Brian Mcdonough, D J Paul E Cowan, L John Wilkerson, Life Sciences Maste Perceptive and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of QTNT stock can currently be purchased for approximately $6.80.

Quotient has a market capitalization of $305.90 million and generates $22.23 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($3.02) on an earnings per share basis. Quotient employs 393 workers across the globe.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.